Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

15
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (2)

Searched Name

H Vioix

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number

Citation Analysis

Yang JH, Kato T, Ahn MJ, Sakai H, Morise M, Chen YM, Han JY, Yang J, Zhao J, Huang JC, Berghoff K, Bruns R, Vioix H, Otto G, Le X, Paik P. 321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open

Ho C, Wong S, Hatswell A, Slater R, Vioix H, Chouaid C. 1180P Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open

Mazieres J, Cortot A, Gezin A, Garcia A, Heeg B, Pfeiffer B, Vioix H. 159P Clinical characteristics of patients with advanced NSCLC and MET exon 14 (METex14) skipping: A systematic literature review. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)02001-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Cortot A, Mazieres J, Gezin A, Garcia A, Heeg B, Pfeiffer B, Vioix H. 158P Prevalence and clinical outcomes of MET exon 14 (METex14) skipping in patients with advanced NSCLC: A systematic literature review. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)02000-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]

Garassino M, Le X, Kowalski D, Migliorino M, Senellert H, Pradera J, Walling R, Kato T, Thomas M, Smit E, Gottfried M, Britschgi C, Johne A, Scheele J, Bruns R, Vioix H, Pfeiffer B, Paik P. MO01.45 Health-Related Quality of Life (HRQoL) in Patients with NSCLC Harboring MET Exon 14 Skipping (METex14) Treated with Tepotinib. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]

Zheng Y, Vioix H, Liu F, Singh B, Sharma S, Sharma S. PATH01.01 Diagnostic and Economic Value of Next-Generation Sequencing (NGS) in Genotyping Non-Small Cell Lung Cancer Tumors (NSCLC): A Literature Review. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]

Garassino M, Le X, Kowalski D, Migliorino M, Senellart H, Pradera JF, Walling R, Kato T, Thomas M, Smit E, Gottfried M, Britschgi C, Johne A, Scheele J, Bruns R, Vioix H, Pfeiffer B, Paik P. 1347P Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open

Charokopou M, Vioix H, Verheggen BG, Bratt T, Franks D. The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective. Value Health 2014;17:A343. [PMID: 27200638 DOI: 10.1016/j.jval.2014.08.689] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]

Charokopou M, Vioix H, Verheggen B, Eddowes LA, Griffiths M, Gabriel Z, Tolley K, Sibartie M. Cost-Effectiveness of Saxagliptin Compared To Glp-1 Analogues As An Add-On To Insulin in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. Value Health 2014;17:A347. [PMID: 27200661 DOI: 10.1016/j.jval.2014.08.711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]

Vioix H, Eddowes LA, Griffiths M, Gabriel Z. Cost-Minimisation Analysis of Saxagliptin Compared to Sitagliptin And Linagliptin As Triple Therapy In Combination With Metformin And A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. Value Health 2014;17:A349. [PMID: 27200670 DOI: 10.1016/j.jval.2014.08.720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]

Charokopou M, Vioix H, Verheggen BG, Dillon S, Franks D. Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective. Value Health 2014;17:A343. [PMID: 27200640 DOI: 10.1016/j.jval.2014.08.690] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]

Charokopou M, Vioix H, Verheggen B, Eddowes LA, Griffiths M, Gabriel Z, Tolley K, Franks D. Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. Value Health 2014;17:A347. [PMID: 27200659 DOI: 10.1016/j.jval.2014.08.709] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]

Charokopou M, Vioix H, Verheggen BG, Maddocks D, Bratt T, Franks D. Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective. Value Health 2014;17:A344-A345. [PMID: 27200644 DOI: 10.1016/j.jval.2014.08.696] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]

Charokopou M, Vioix H, Eddowes LA, Griffiths M, Verheggen BG, Gabriel Z, Tolley K. Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. Value Health 2014;17:A347. [PMID: 27200660 DOI: 10.1016/j.jval.2014.08.710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]

Vioix H, Eddowes LA, Griffiths M, Gabriel Z. Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. Value Health 2014;17:A348. [PMID: 27200667 DOI: 10.1016/j.jval.2014.08.717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]